Jones R, Nelson M
St Stephens Centre, Chelsea and Westminster Hospital, London, UK.
Int J Clin Pract. 2006 Oct;60(10):1295-9. doi: 10.1111/j.1742-1241.2006.01143.x.
Although preventable by vaccination, hepatitis B infection is common, affecting more than 350 million individuals worldwide. Chronic hepatitis B infection is associated with the complications of chronic liver disease including cirrhosis and hepatocellular carcinoma. Current agents designed to target hepatitis B are hindered by the development of resistance, poor tolerability or limited efficacy and a demand for new agents and strategies continues. This review focuses on telbivudine, a novel agent in the fight against hepatitis B.
尽管乙肝感染可通过接种疫苗预防，但它仍很常见，全球有超过3.5亿人受其影响。慢性乙肝感染与包括肝硬化和肝细胞癌在内的慢性肝病并发症相关。目前针对乙肝的药物受到耐药性、耐受性差或疗效有限的阻碍，因此对新药物和新策略的需求持续存在。本综述聚焦于替比夫定，一种对抗乙肝的新型药物。
